Nitric oxide (NO) production is essential to facilitate rises in uterine blood flow (UBF) during pregnancy. It has been proposed that the metabolites of Eβ, 2-hydroxyestradiol (2-OHE), 4-hydroxyestradiol (4-OHE), 2-methoxyestradiol (2-ME), and 4-methoxyestradiol (4-ME) play a role in mediating vasodilation and rises in UBF during pregnancy. We previously showed that the Eβ metabolites stimulate prostacyclin production in pregnancy-derived ovine uterine artery endothelial cells (P-UAECs); however, it is unknown whether the Eβ metabolites also induce NO production. Herein, UAECs derived from nonpregnant and pregnant ewes were used to test the hypothesis that Eβ metabolites stimulate NO production in a pregnancy-specific manner. Specific estrogen receptor (ER) and adrenergic receptor (AR) antagonists were used to determine the roles of ERs or ARs in Eβ metabolite-induced NO production. Eβ and its metabolites increased total nitric oxide metabolites (NOx) levels (NO + NO) in P-UAECs, but not in NP-UAECs. Pretreatment with combined 1 µmol/L 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP; ER-α antagonist) and 1 µmol/L 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP; ER-β antagonist) inhibited the rises in NOx levels stimulated by Eβ and 2-ME, but had no effect on 2-OHE-, 4-OHE-, or 4-ME-stimulated rises in NOx levels. Pretreatment with yohimbine (α-AR antagonist) and propranolol (β-AR antagonist) inhibited the rises in NOx levels stimulated by 2-OHE, but not by Eβ, 4-OHE, 2-ME, or 4-ME. These data demonstrate that Eβ metabolites stimulate NO synthesis via ERs or ARs in UAECs in a pregnancy-specific manner, suggesting that these metabolites contribute to rises in vasodilation and UBF during pregnancy.